cp-609754
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2000 (NCT00006085)
Timeline
2000s
- Jan 1, 2000
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Protein farnesyltransferaseINHIBITOR
Protein farnesyltransferase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C#Cc1cccc(-c2cc(=O)n(C)c3ccc([C@](O)(c4ccc(Cl)cc4)c4cncn4C)cc23)c1- Mol. weight
- 479.97 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297367 ↗
Also known as
- cp 609754
- cp 609,754
- cp-609754
- cp-609754
- cp-609,754
- cp-609,754
- cp-609,754
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00006085 | Phase 1 | Jun 1, 2000 | National Cancer Institute (NCI), University of South Florida |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2000 |
| University of South Florida | Academic/Hospital | 1 | 1 | 1 | 2000 |
2 organizations
Page 1 / 1